| Dr Jillian Tessier, PHD | |
|
100 Shoreline Hwy, Building B, Suite 100, Mill Valley, CA 94941 | |
| (415) 877-4408 | |
| Not Available |
| Full Name | Dr Jillian Tessier |
|---|---|
| Gender | Female |
| Speciality | Psychologist |
| Location | 100 Shoreline Hwy, Mill Valley, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093494544 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | PSY34187 (California) | Primary |
| Entity Name | K&m Neuropsychology, A Psychology Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760900831 PECOS PAC ID: 8921373184 Enrollment ID: O20171013002637 |
News Archive
Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the U.S. Food and Drug Administration (FDA) has accepted Labopharm's response regarding its novel formulation of the antidepressant trazodone as complete and designated it as a Class 2 resubmission. The FDA has assigned Labopharm a new Prescription Drug User Fee Act (PDUFA) action date of February 11, 2010.
The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumours in both skin and liver. It has long been known to have a direct role in reducing the expression of a gene (p53) that leads to the death of abnormal cells and to activate transcription of a further gene (CyclinD1) that directly promotes cell division.
In his Foreign Policy column, "The Optimist," Charles Kenny, a senior fellow at the Center for Global Development and a Schwartz fellow at the New America Foundation, responds to a speech to G20 leaders last week by Bill Gates, co-chair of the Bill & Melinda Gates Foundation, in which he "suggested that a financial transactions tax, alongside additional taxes on tobacco and carbon, could be used to help rich countries meet a global target of committing 0.7 percent of GDP to development aid."
Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC administration of Herceptin compared to the standard IV infusion.1 Presented at the St. Gallen Breast Cancer Conference in Switzerland.
Ironwood Pharmaceuticals, Inc. announced today the pricing of an underwritten public offering of 5,250,000 shares of its Class A common stock at a price of $15.09 per share to the public. All of the shares are being offered by Ironwood.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jillian Tessier, PHD 100 Shoreline Hwy, Building B, Suite 100, Mill Valley, CA 94941 Ph: (415) 877-4408 | Dr Jillian Tessier, PHD 100 Shoreline Hwy, Building B, Suite 100, Mill Valley, CA 94941 Ph: (415) 877-4408 |
News Archive
Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the U.S. Food and Drug Administration (FDA) has accepted Labopharm's response regarding its novel formulation of the antidepressant trazodone as complete and designated it as a Class 2 resubmission. The FDA has assigned Labopharm a new Prescription Drug User Fee Act (PDUFA) action date of February 11, 2010.
The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumours in both skin and liver. It has long been known to have a direct role in reducing the expression of a gene (p53) that leads to the death of abnormal cells and to activate transcription of a further gene (CyclinD1) that directly promotes cell division.
In his Foreign Policy column, "The Optimist," Charles Kenny, a senior fellow at the Center for Global Development and a Schwartz fellow at the New America Foundation, responds to a speech to G20 leaders last week by Bill Gates, co-chair of the Bill & Melinda Gates Foundation, in which he "suggested that a financial transactions tax, alongside additional taxes on tobacco and carbon, could be used to help rich countries meet a global target of committing 0.7 percent of GDP to development aid."
Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC administration of Herceptin compared to the standard IV infusion.1 Presented at the St. Gallen Breast Cancer Conference in Switzerland.
Ironwood Pharmaceuticals, Inc. announced today the pricing of an underwritten public offering of 5,250,000 shares of its Class A common stock at a price of $15.09 per share to the public. All of the shares are being offered by Ironwood.
› Verified 4 days ago
Dr. Jonathan David Mahrer, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 61 Camino Alto Ste 106, Mill Valley, CA 94941 Phone: 415-567-7751 Fax: 866-295-5532 | |
Dr. Nancy Novack, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 240 Almonte Blvd, Mill Valley, CA 94941 Phone: 415-383-3058 Fax: 415-383-5306 | |
Dr. Joanie Gillispie, PH.D Psychologist Medicare: Not Enrolled in Medicare Practice Location: 9 Castle Rock Dr, Mill Valley, CA 94941 Phone: 415-380-9985 | |
Dr. Julie Axelrod Austin, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 240 Miller Ave Ste G, Mill Valley, CA 94941 Phone: 415-928-7800 | |
Dr. Melanie Greenberg, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 150 Shoreline Hwy, Building B, Suite 22, Mill Valley, CA 94941 Phone: 415-742-8062 Fax: 415-742-8062 | |
Dr. Timothy F Salz, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 275 Miller Ave, Mill Valley, CA 94941 Phone: 415-458-1904 Fax: 415-388-7253 |